Abstract: A method of image projection including selecting a set of desired chromaticity coordinates of a projection system, the projection system including a plurality of laser sources; determining a set of parameters of an expected operational environment; and configuring each laser source to have a power ratio and a power spectrum density function generating a normalized power spectrum density function of the projection system having the set of desired chromaticity coordinates and a wavelength diversity factor of at least 2 in the expected operational environment. A projection system including an input device configured to receive a set of desired chromaticity coordinates and a set of operational parameters; a plurality of laser sources each having a power ratio and a power spectrum density function configured to generate a normalized power spectrum density function producing the set of desired chromaticity coordinates and a wavelength diversity factor of at least 2.

Abstract: An object symmetry axis detection method based on an RGB-D camera includes: obtaining three-dimensional point cloud data of an image of a target object in natural scenes, identifying data corresponding to a point cloud of an area where the target object is located from the three-dimensional point cloud data according to a color difference threshold segmentation method, establishing a spherical coordinate system centering about a centroid of the target point cloud data, selecting n2 candidate symmetry planes with a spherical coordinate system segmentation method, and calculating a symmetry axis of the target point cloud data according to the n2 candidate symmetry planes as the symmetry axis of the target object.

Abstract: The invention provides an inner limiting membrane peeling model that is used in procedure training in peeling of the inner limiting membrane. The model has: a simulated retina and a simulated inner limiting membrane formed on the simulated retina. The simulated inner limiting membrane is formed of a hydrophilic polymer gel that is formed mainly of a water-soluble polymer. At least when used in the above procedure training, the model is disposed with the simulated inner limiting membrane immersed in water or an aqueous solution containing a predetermined solute.

Abstract: An atomic layer deposition method is provided. The atomic layer deposition method includes the following steps. A substrate is placed in a reaction chamber. At least one deposition cycle is performed to deposit a metal film on the substrate. The at least one deposition cycle includes the following steps. A metal precursor is introduced in the reaction chamber. A hydrogen plasma is introduced to be reacted with the metal precursor adsorbed on the substrate to form the metal film. An annealing process is performed on the metal film. The at least one deposition cycle is performed in a hydrogen atmosphere under UV light irradiation.

Abstract: Monopole rectenna arrays distributed over a curved surface for multi-directional, multi-polarization, and multi-band ambient RF energy harvesting in accordance with embodiments of the invention are disclosed. In one embodiment, a rectenna array includes a curved grounding surface, a plurality of multi-band antennas distributed across the surface of the curved grounding surface and configured to harvest RF energy in multiple spectral bands, from multiple directions, and with multiple polarizations, a multi-band rectifier connected to an output of each of the plurality of multi-band antennas, and a direct current (DC) combiner including a plurality of inputs connected to outputs of the multi-band rectifiers and an output configured to provide DC power to a load.

Abstract: An automated warehouse storage and retrieval system may comprise at least an aisle, and each of two sides of the aisle has a shelf. A rail is laid along the aisle to enable at least an automated vehicle to move thereon. The automated vehicle has a platform, and a top surface thereof comprises at least a working station and at least a pick-and-place unit. Each of two lateral sides of the platform has two openings separated by a desired distance, and each of the openings has a climbing unit installed therein. The climbing units are configured to synchronously protrude from or move back in the openings. A side of the shelf faced to the rail has a plurality of vertical supporting members arranged in parallel, and each two adjacent supporting members are separated by the distance same as the two climbing units on the same lateral side of the platform.

Abstract: Slurry compositions useable in chemical mechanical polishing processes, as well as methods of making and methods of using the same, are described.

Abstract: Described herein are compositions including an immune effector cells that are chemically modified at the surface with one or more active agent-loaded nano- or micro-particles for controlled release of the active agent. Exemplary drug-loaded nanoparticles include crosslinked multilayer liposome (CMLV) encapsulating an A2a receptor inhibitor. The modified immune effector cells may also present one or more chimeric antigen receptors (CARs) on the surface. Also provided are methods of using the same to treat cancer.

Abstract: Provided herein are methods for treatment of a neurodegenerative disease, such as Late Infantile Neuronal Ceroid Lipofuscinosis, including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent comprising a fibrate.

Abstract: The present disclosure generally relates to a circularized peptide for treating cancer. An cyclic peptide is disclosed that has an amino acid sequence selected from Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 3), (SEQ ID NO: 4), Lys-Gly-X6-Val-Leu-Gln-Met-X7-X8-X9-Leu-Val (SEQ ID NO: 5), Lys-X5-Glu-X1-X2-Gln-X12-Glu-Asp-Asp-X3-X4 (SEQ ID NO: 9), and X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4 (SEQ ID NO: 10). The amino acids X1, X2, X3, and X4 can be each independently valine, leucine, isoleucine, or alanine; X5 can be glycine, alanine, leucine, isoleucine, or valine; X6, X7, X8, and X9 can be each independently glutamic acid or asparagine; X10 can be lysine or arginine; X11 can be methionine or cysteine; and X12 can be methionine or norleucine. The cyclic peptide can have the amino acid sequence Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val (SEQ ID NO: 1).

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

Abstract: Provided is a method of manufacturing a nano-catalyst filter, which includes depositing through electrodeposition a catalyst precursor inside a porous filter to which an electrode layer is attached. Using this method, a nano-catalyst can be uniformly deposited inside a porous ceramic filter, and high catalyst efficiency can be obtained only using a small amount of the nano-catalyst.

Abstract: Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).

Abstract: A compound having a first ligand LA of Formula I, is disclosed. In the structure of Formula I, Z1 through Z7 are each independently C or N; ring B is a 5-membered or 6-membered ring; each RA, RB, and RC is independently hydrogen or one of a variety of substituents; any two substituents in RC may be joined or fused together to form a ring. In the compound, LA is complexed to a metal M, which is optionally coordinated to other ligands. In addition, ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate, or hexadentate ligand. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

Abstract: This disclosure describes compositions and methods for enhanced production of enduracidin in genetically engineered strains of Streptomycesfungicidicus. In particular, the present disclosure describes the genetic manipulation of regulatory genes orf24 and orf18 associated with the enduracidin (enramycin) biosynthesis gene cluster from Streptomyces fungicidicus to generate vector constructs and recombinant strains producing greater yields of enduracidin.

Abstract: The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

Abstract: Compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds and can be effective when a particular cancer has become resistant to previously administered therapies.

Abstract: Disclosed are methods and systems for screening covalent ligand libraries to identify potential covalent inhibitors. The methods and systems may also be used to generate a covalent inhibitor library from natural ligands. These covalent inhibitors bind to the receptor irreversibly after initial reversible binding. The covalent inhibitor identified or designed using the present methods may specifically bind to and covalently modify a receptor.

Abstract: The present disclosure provides compounds of any one of Formulae (I?), (I), (IA), (II?), (II), (IIA), (IIIA), (III?), (III?), (III), (IIIA), (IV), (V?), (V), (VI), (VII), (VIII?), (VIII), (IX?), (IX), and (X). The compounds described herein may be useful in treating and/or preventing abroad range of diseases (e.g., proliferative disease (e.g., cancers (e.g., non-small cell lung cancer, or glioma), inflammatory diseases, autoimmune diseases), CNS disorder (e.g., drug addiction), metabolic disorder (e.g., diabetes), or infectious disease (e.g., bacterial infection or parasitic infection (e.g., malaria))). Also provided in the present disclosure are pharmaceutical compositions, methods of synthesis of a compound described herein, kits, methods, and uses including or using a compound described herein.

Abstract: A liquid crystal display is configured such that a composite layer thereof is transparent to incident light in one voltage condition (e.g., in the absence of an applied voltage) and scatters incident light out of the display in another voltage condition (e.g., when a voltage is applied). The liquid crystal display does not need polarizers or color filters.